ID   TOPRS_HUMAN             Reviewed;        1045 AA.
AC   Q9NS56; O43273; Q6P987; Q9NS55; Q9UNR9;
DT   18-APR-2006, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   10-MAY-2017, entry version 140.
DE   RecName: Full=E3 ubiquitin-protein ligase Topors;
DE            EC=2.3.2.27;
DE   AltName: Full=RING-type E3 ubiquitin transferase Topors {ECO:0000305};
DE   AltName: Full=SUMO1-protein E3 ligase Topors;
DE   AltName: Full=Topoisomerase I-binding RING finger protein;
DE   AltName: Full=Topoisomerase I-binding arginine/serine-rich protein;
DE   AltName: Full=Tumor suppressor p53-binding protein 3;
DE            Short=p53-binding protein 3;
DE            Short=p53BP3;
GN   Name=TOPORS; Synonyms=LUN, TP53BPL;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INTERACTION WITH TOP1, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=10352183; DOI=10.1093/nar/27.12.2538;
RA   Haluska P. Jr., Saleem A., Rasheed Z., Ahmed F., Su E.W., Liu L.F.,
RA   Rubin E.H.;
RT   "Interaction between human topoisomerase I and a novel RING
RT   finger/arginine-serine protein.";
RL   Nucleic Acids Res. 27:2538-2544(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), PUTATIVE DNA-BINDING,
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RC   TISSUE=Lung;
RX   PubMed=11278651; DOI=10.1074/jbc.M010262200;
RA   Chu D., Kakazu N., Gorrin-Rivas M.J., Lu H.P., Kawata M., Abe T.,
RA   Ueda K., Adachi Y.;
RT   "Cloning and characterization of LUN, a novel RING-finger protein that
RT   is highly expressed in lung and specifically binds to a palindromic
RT   sequence.";
RL   J. Biol. Chem. 276:14004-14013(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS
RP   THR-154; LYS-517 AND ASP-749.
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 51-1045 (ISOFORM 1), INTERACTION WITH
RP   TP53, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=10415337; DOI=10.1016/S0378-1119(99)00203-6;
RA   Zhou R., Wen H., Ao S.-Z.;
RT   "Identification of a novel gene encoding a p53-associated protein.";
RL   Gene 235:93-101(1999).
RN   [6]
RP   SUBCELLULAR LOCATION.
RX   PubMed=12083797; DOI=10.1006/excr.2002.5550;
RA   Rasheed Z.A., Saleem A., Ravee Y., Pandolfi P.P., Rubin E.H.;
RT   "The topoisomerase I-binding RING protein, topors, is associated with
RT   promyelocytic leukemia nuclear bodies.";
RL   Exp. Cell Res. 277:152-160(2002).
RN   [7]
RP   INTERACTION WITH SUMO1 AND UBE2I, SUBCELLULAR LOCATION, SUMOYLATION,
RP   AND MUTAGENESIS OF LYS-76; LYS-301; LYS-485; LYS-560 AND LYS-921.
RX   PubMed=14516784; DOI=10.1016/S0014-4827(03)00292-1;
RA   Weger S., Hammer E., Engstler M.;
RT   "The DNA topoisomerase I binding protein topors as a novel cellular
RT   target for SUMO-1 modification: characterization of domains necessary
RT   for subcellular localization and sumolation.";
RL   Exp. Cell Res. 290:13-27(2003).
RN   [8]
RP   FUNCTION, AND MUTAGENESIS OF TRP-131.
RX   PubMed=15247280; DOI=10.1074/jbc.C400300200;
RA   Rajendra R., Malegaonkar D., Pungaliya P., Marshall H., Rasheed Z.,
RA   Brownell J., Liu L.F., Lutzker S., Saleem A., Rubin E.H.;
RT   "Topors functions as an E3 ubiquitin ligase with specific E2 enzymes
RT   and ubiquitinates p53.";
RL   J. Biol. Chem. 279:36440-36444(2004).
RN   [9]
RP   REDUCED EXPRESSION IN LUNG CANCERS.
RX   PubMed=15364129; DOI=10.1016/j.lungcan.2004.03.009;
RA   Oyanagi H., Takenaka K., Ishikawa S., Kawano Y., Adachi Y., Ueda K.,
RA   Wada H., Tanaka F.;
RT   "Expression of LUN gene that encodes a novel RING finger protein is
RT   correlated with development and progression of non-small cell lung
RT   cancer.";
RL   Lung Cancer 46:21-28(2004).
RN   [10]
RP   TISSUE SPECIFICITY, AND REDUCED EXPRESSION IN COLON CANCERS.
RX   PubMed=15107820; DOI=10.1038/sj.onc.1207700;
RA   Saleem A., Dutta J., Malegaonkar D., Rasheed F., Rasheed Z.,
RA   Rajendra R., Marshall H., Luo M., Li H., Rubin E.H.;
RT   "The topoisomerase I- and p53-binding protein topors is differentially
RT   expressed in normal and malignant human tissues and may function as a
RT   tumor suppressor.";
RL   Oncogene 23:5293-5300(2004).
RN   [11]
RP   FUNCTION, AND SUMOYLATION.
RX   PubMed=16122737; DOI=10.1016/j.febslet.2005.07.088;
RA   Weger S., Hammer E., Heilbronn R.;
RT   "Topors acts as a SUMO-1 E3 ligase for p53 in vitro and in vivo.";
RL   FEBS Lett. 579:5007-5012(2005).
RN   [12]
RP   FUNCTION, AND INDUCTION.
RX   PubMed=15735665; DOI=10.1038/sj.onc.1208554;
RA   Lin L., Ozaki T., Takada Y., Kageyama H., Nakamura Y., Hata A.,
RA   Zhang J.H., Simonds W.F., Nakagawara A., Koseki H.;
RT   "Topors, a p53 and topoisomerase I-binding RING finger protein, is a
RT   coactivator of p53 in growth suppression induced by DNA damage.";
RL   Oncogene 24:3385-3396(2005).
RN   [13]
RP   INVOLVEMENT IN RP31.
RX   PubMed=17924349; DOI=10.1086/521953;
RA   Chakarova C.F., Papaioannou M.G., Khanna H., Lopez I., Waseem N.,
RA   Shah A., Theis T., Friedman J., Maubaret C., Bujakowska K.,
RA   Veraitch B., El-Aziz M.M.A., Prescott de Q., Parapuram S.K.,
RA   Bickmore W.A., Munro P.M.G., Gal A., Hamel C.P., Marigo V.,
RA   Ponting C.P., Wissinger B., Zrenner E., Matter K., Swaroop A.,
RA   Koenekoop R.K., Bhattacharya S.S.;
RT   "Mutations in TOPORS cause autosomal dominant retinitis pigmentosa
RT   with perivascular retinal pigment epithelium atrophy.";
RL   Am. J. Hum. Genet. 81:1098-1103(2007).
RN   [14]
RP   FUNCTION, AND INTERACTION WITH SIN3A.
RX   PubMed=17803295; DOI=10.1021/pr0703674;
RA   Pungaliya P., Kulkarni D., Park H.J., Marshall H., Zheng H.,
RA   Lackland H., Saleem A., Rubin E.H.;
RT   "TOPORS functions as a SUMO-1 E3 ligase for chromatin-modifying
RT   proteins.";
RL   J. Proteome Res. 6:3918-3923(2007).
RN   [15]
RP   PHOSPHORYLATION AT SER-98; SER-499; SER-585 AND SER-866, MUTAGENESIS
RP   OF SER-98, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=19053840; DOI=10.1021/bi801904q;
RA   Park H.J., Zheng H., Kulkarni D., Kerrigan J., Pungaliya P.,
RA   Saleem A., Rubin E.H.;
RT   "Identification of phosphorylation sites of TOPORS and a role for
RT   serine 98 in the regulation of ubiquitin but not SUMO E3 ligase
RT   activity.";
RL   Biochemistry 47:13887-13896(2008).
RN   [16]
RP   FUNCTION, INTERACTION WITH NKX3-1, AND SUBCELLULAR LOCATION.
RX   PubMed=18077445; DOI=10.1074/jbc.M708630200;
RA   Guan B., Pungaliya P., Li X., Uquillas C., Mutton L.N., Rubin E.H.,
RA   Bieberich C.J.;
RT   "Ubiquitination by TOPORS regulates the prostate tumor suppressor
RT   NKX3.1.";
RL   J. Biol. Chem. 283:4834-4840(2008).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-98, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [19]
RP   FUNCTION, INTERACTION WITH PLK1, PHOSPHORYLATION AT SER-718 BY PLK1,
RP   MUTAGENESIS OF SER-718, AND SUBCELLULAR LOCATION.
RX   PubMed=19473992; DOI=10.1074/jbc.C109.001560;
RA   Yang X., Li H., Zhou Z., Wang W.H., Deng A., Andrisani O., Liu X.;
RT   "Plk1-mediated phosphorylation of Topors regulates p53 stability.";
RL   J. Biol. Chem. 284:18588-18592(2009).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-98; SER-864 AND SER-866,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [21]
RP   FUNCTION, INTERACTION WITH IKBKE, AND SUBCELLULAR LOCATION.
RX   PubMed=20188669; DOI=10.1016/j.molcel.2010.01.018;
RA   Renner F., Moreno R., Schmitz M.L.;
RT   "SUMOylation-dependent localization of IKKepsilon in PML nuclear
RT   bodies is essential for protection against DNA-damage-triggered cell
RT   death.";
RL   Mol. Cell 37:503-515(2010).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-98, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-98; SER-864 AND SER-866,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-98; SER-194; SER-585 AND
RP   SER-734, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-98, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [26]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-76; LYS-83; LYS-249 AND
RP   LYS-701, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [27]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-76 AND LYS-701, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033;
RA   Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "SUMO-2 orchestrates chromatin modifiers in response to DNA damage.";
RL   Cell Rep. 10:1778-1791(2015).
RN   [28]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-76 AND LYS-701, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25755297; DOI=10.1074/mcp.O114.044792;
RA   Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "System-wide analysis of SUMOylation dynamics in response to
RT   replication stress reveals novel small ubiquitin-like modified target
RT   proteins and acceptor lysines relevant for genome stability.";
RL   Mol. Cell. Proteomics 14:1419-1434(2015).
CC   -!- FUNCTION: Functions as an E3 ubiquitin-protein ligase and as an E3
CC       SUMO1-protein ligase. Probable tumor suppressor involved in cell
CC       growth, cell proliferation and apoptosis that regulates p53/TP53
CC       stability through ubiquitin-dependent degradation. May regulate
CC       chromatin modification through sumoylation of several chromatin
CC       modification-associated proteins. May be involved in DNA damage-
CC       induced cell death through IKBKE sumoylation.
CC       {ECO:0000269|PubMed:15247280, ECO:0000269|PubMed:15735665,
CC       ECO:0000269|PubMed:16122737, ECO:0000269|PubMed:17803295,
CC       ECO:0000269|PubMed:18077445, ECO:0000269|PubMed:19473992,
CC       ECO:0000269|PubMed:20188669}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugating
CC       enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-
CC       conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptor
CC       protein]-L-lysine.
CC   -!- SUBUNIT: Interacts with PARK7/DJ-1 (By similarity). Interacts with
CC       TOP1. Interacts with p53/TP53; can both ubiquitinate and sumoylate
CC       p53/TP53. Interacts with the SUMO1 conjugating enzyme UBE2I.
CC       Interacts with SUMO1. Interacts with NKX3-1; polyubiquitinates
CC       NKX3-1 and induces its proteasomal degradation. Interacts with
CC       SIN3A; sumoylates SIN3A. Interacts with IKBKE; induced by DNA
CC       damage. {ECO:0000250|UniProtKB:Q80Z37,
CC       ECO:0000269|PubMed:10352183, ECO:0000269|PubMed:10415337,
CC       ECO:0000269|PubMed:14516784, ECO:0000269|PubMed:17803295,
CC       ECO:0000269|PubMed:18077445, ECO:0000269|PubMed:19473992,
CC       ECO:0000269|PubMed:20188669}.
CC   -!- INTERACTION:
CC       P03132:Rep68 (xeno); NbExp=3; IntAct=EBI-1996473, EBI-7387242;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Nucleus, PML body. Note=Localizes
CC       to discrete nuclear foci which partly overlap with PML nuclear
CC       bodies. Targeted to PML nuclear bodies upon DNA damage.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=LUN-1;
CC         IsoId=Q9NS56-1; Sequence=Displayed;
CC       Name=2; Synonyms=LUN-2;
CC         IsoId=Q9NS56-2; Sequence=VSP_017916, VSP_017917;
CC   -!- TISSUE SPECIFICITY: Expressed at highest levels in testis and at
CC       lower levels in adrenal gland, bone marrow, brain, colon, heart,
CC       kidney, liver, muscle, ovary, pancreas, placenta, prostate,
CC       skeletal muscle, skin, small intestine, spleen, stomach, testis,
CC       thymus, thyroid and uterus. Expressed in the alveolar epithelium
CC       of the lung. Expression is commonly decreased in colon
CC       adenocarcinomas and lung cancers. {ECO:0000269|PubMed:10415337,
CC       ECO:0000269|PubMed:11278651, ECO:0000269|PubMed:15107820}.
CC   -!- INDUCTION: By genotoxic agents such as cisplatin and camptothecin.
CC       {ECO:0000269|PubMed:15735665}.
CC   -!- PTM: Phosphorylation at Ser-98 regulates the E3 ubiquitin-protein
CC       ligase activity but not the SUMO1-protein ligase activity.
CC       Phosphorylation at Ser-718 increases the E3 ubiquitin-protein
CC       ligase activity versus the SUMO1-protein ligase activity resulting
CC       in increased p53/TP53 ubiquitination and degradation.
CC       {ECO:0000269|PubMed:19053840, ECO:0000269|PubMed:19473992}.
CC   -!- PTM: Sumoylated. {ECO:0000269|PubMed:14516784,
CC       ECO:0000269|PubMed:16122737}.
CC   -!- DISEASE: Retinitis pigmentosa 31 (RP31) [MIM:609923]: A retinal
CC       dystrophy belonging to the group of pigmentary retinopathies.
CC       Retinitis pigmentosa is characterized by retinal pigment deposits
CC       visible on fundus examination and primary loss of rod
CC       photoreceptor cells followed by secondary loss of cone
CC       photoreceptors. Patients typically have night vision blindness and
CC       loss of midperipheral visual field. As their condition progresses,
CC       they lose their far peripheral visual field and eventually central
CC       vision as well. {ECO:0000269|PubMed:17924349}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- CAUTION: Was originally thought to bind to the palindromic
CC       consensus sequence 5'-TCCCAGCACTTTGGGA-3' and to regulate the
CC       transcription of numerous genes in the lung.
CC       {ECO:0000305|PubMed:11278651}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC98530.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/TOPORSID42663ch9p21.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF098300; AAD23379.1; -; mRNA.
DR   EMBL; AB045732; BAB03714.1; -; mRNA.
DR   EMBL; AB045733; BAB03715.1; -; mRNA.
DR   EMBL; AL353671; CAH71253.1; -; Genomic_DNA.
DR   EMBL; AL353671; CAH71254.1; -; Genomic_DNA.
DR   EMBL; BC060884; AAH60884.1; -; mRNA.
DR   EMBL; U82939; AAC98530.1; ALT_INIT; mRNA.
DR   CCDS; CCDS56566.1; -. [Q9NS56-2]
DR   CCDS; CCDS6527.1; -. [Q9NS56-1]
DR   RefSeq; NP_001182551.1; NM_001195622.1. [Q9NS56-2]
DR   RefSeq; NP_005793.2; NM_005802.4. [Q9NS56-1]
DR   UniGene; Hs.589962; -.
DR   ProteinModelPortal; Q9NS56; -.
DR   SMR; Q9NS56; -.
DR   BioGrid; 115505; 64.
DR   IntAct; Q9NS56; 19.
DR   MINT; MINT-94004; -.
DR   STRING; 9606.ENSP00000353735; -.
DR   iPTMnet; Q9NS56; -.
DR   PhosphoSitePlus; Q9NS56; -.
DR   BioMuta; TOPORS; -.
DR   DMDM; 74752935; -.
DR   EPD; Q9NS56; -.
DR   MaxQB; Q9NS56; -.
DR   PaxDb; Q9NS56; -.
DR   PeptideAtlas; Q9NS56; -.
DR   PRIDE; Q9NS56; -.
DR   Ensembl; ENST00000360538; ENSP00000353735; ENSG00000197579. [Q9NS56-1]
DR   Ensembl; ENST00000379858; ENSP00000369187; ENSG00000197579. [Q9NS56-2]
DR   GeneID; 10210; -.
DR   KEGG; hsa:10210; -.
DR   UCSC; uc003zrb.4; human. [Q9NS56-1]
DR   CTD; 10210; -.
DR   DisGeNET; 10210; -.
DR   GeneCards; TOPORS; -.
DR   GeneReviews; TOPORS; -.
DR   HGNC; HGNC:21653; TOPORS.
DR   HPA; HPA060640; -.
DR   HPA; HPA065661; -.
DR   MalaCards; TOPORS; -.
DR   MIM; 609507; gene.
DR   MIM; 609923; phenotype.
DR   neXtProt; NX_Q9NS56; -.
DR   OpenTargets; ENSG00000197579; -.
DR   Orphanet; 791; Retinitis pigmentosa.
DR   PharmGKB; PA134979531; -.
DR   eggNOG; KOG4430; Eukaryota.
DR   eggNOG; ENOG410XQZR; LUCA.
DR   GeneTree; ENSGT00530000064170; -.
DR   HOGENOM; HOG000231723; -.
DR   HOVERGEN; HBG080410; -.
DR   InParanoid; Q9NS56; -.
DR   KO; K10631; -.
DR   OMA; DIINFRR; -.
DR   OrthoDB; EOG091G089U; -.
DR   PhylomeDB; Q9NS56; -.
DR   TreeFam; TF339497; -.
DR   SIGNOR; Q9NS56; -.
DR   ChiTaRS; TOPORS; human.
DR   GeneWiki; TOPORS; -.
DR   GenomeRNAi; 10210; -.
DR   PRO; PR:Q9NS56; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; ENSG00000197579; -.
DR   CleanEx; HS_TOPORS; -.
DR   Genevisible; Q9NS56; HS.
DR   GO; GO:0005814; C:centriole; IDA:BHF-UCL.
DR   GO; GO:0036064; C:ciliary basal body; IDA:BHF-UCL.
DR   GO; GO:0000930; C:gamma-tubulin complex; IDA:BHF-UCL.
DR   GO; GO:0030496; C:midbody; TAS:BHF-UCL.
DR   GO; GO:0016607; C:nuclear speck; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0032391; C:photoreceptor connecting cilium; IDA:BHF-UCL.
DR   GO; GO:0016605; C:PML body; IDA:UniProtKB.
DR   GO; GO:0000922; C:spindle pole; IDA:BHF-UCL.
DR   GO; GO:0000151; C:ubiquitin ligase complex; IDA:BHF-UCL.
DR   GO; GO:0003823; F:antigen binding; IPI:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; IDA:UniProtKB.
DR   GO; GO:0044547; F:DNA topoisomerase binding; IPI:UniProtKB.
DR   GO; GO:0019789; F:SUMO transferase activity; IDA:UniProtKB.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IDA:BHF-UCL.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IDA:UniProtKB.
DR   GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; IDA:UniProtKB.
DR   GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IEA:Ensembl.
DR   GO; GO:0051457; P:maintenance of protein location in nucleus; IDA:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; ISS:BHF-UCL.
DR   GO; GO:0035845; P:photoreceptor cell outer segment organization; ISS:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IEA:Ensembl.
DR   GO; GO:0051443; P:positive regulation of ubiquitin-protein transferase activity; IDA:BHF-UCL.
DR   GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IMP:UniProtKB.
DR   GO; GO:0070936; P:protein K48-linked ubiquitination; IDA:BHF-UCL.
DR   GO; GO:0034504; P:protein localization to nucleus; IMP:UniProtKB.
DR   GO; GO:0006513; P:protein monoubiquitination; IDA:BHF-UCL.
DR   GO; GO:0000209; P:protein polyubiquitination; IDA:BHF-UCL.
DR   GO; GO:0016925; P:protein sumoylation; IDA:UniProtKB.
DR   GO; GO:0042127; P:regulation of cell proliferation; IEA:Ensembl.
DR   GO; GO:0010842; P:retina layer formation; ISS:BHF-UCL.
DR   GO; GO:0046549; P:retinal cone cell development; ISS:BHF-UCL.
DR   GO; GO:0046548; P:retinal rod cell development; ISS:BHF-UCL.
DR   GO; GO:0006351; P:transcription, DNA-templated; NAS:UniProtKB.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IMP:UniProtKB.
DR   CDD; cd00162; RING; 1.
DR   Gene3D; 3.30.40.10; -; 1.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   InterPro; IPR017907; Znf_RING_CS.
DR   SMART; SM00184; RING; 1.
DR   PROSITE; PS00518; ZF_RING_1; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Complete proteome; DNA damage; Isopeptide bond;
KW   Metal-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Retinitis pigmentosa; Transferase;
KW   Ubl conjugation; Ubl conjugation pathway; Zinc; Zinc-finger.
FT   CHAIN         1   1045       E3 ubiquitin-protein ligase Topors.
FT                                /FTId=PRO_0000232626.
FT   ZN_FING     103    142       RING-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00175}.
FT   REGION        1    195       E3 ubiquitin-protein ligase activity.
FT   REGION       51    374       Required for DNA-binding.
FT   REGION      437    654       Interaction with SUMO1.
FT                                {ECO:0000269|PubMed:14516784}.
FT   REGION      437    574       Required for sumoylation and localization
FT                                to discrete nuclear foci.
FT   REGION      456    882       Interaction with TOP1.
FT                                {ECO:0000269|PubMed:10352183}.
FT   REGION      456    731       Interaction with p53/TP53.
FT                                {ECO:0000269|PubMed:10415337}.
FT   REGION      854    917       Interaction with UBE2I.
FT                                {ECO:0000269|PubMed:14516784}.
FT   COMPBIAS    579    788       Arg-rich.
FT   COMPBIAS    854    895       Lys-rich.
FT   MOD_RES      98     98       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569,
FT                                ECO:0000269|PubMed:19053840}.
FT   MOD_RES     194    194       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     499    499       Phosphoserine.
FT                                {ECO:0000269|PubMed:19053840}.
FT   MOD_RES     585    585       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:19053840}.
FT   MOD_RES     718    718       Phosphoserine; by PLK1.
FT                                {ECO:0000269|PubMed:19473992}.
FT   MOD_RES     734    734       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     864    864       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:21406692}.
FT   MOD_RES     866    866       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000269|PubMed:19053840}.
FT   MOD_RES     912    912       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q80Z37}.
FT   MOD_RES     914    914       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q80Z37}.
FT   MOD_RES    1028   1028       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q80Z37}.
FT   CROSSLNK     76     76       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:25218447,
FT                                ECO:0000244|PubMed:25755297,
FT                                ECO:0000244|PubMed:25772364}.
FT   CROSSLNK     83     83       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:25218447}.
FT   CROSSLNK    249    249       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:25218447}.
FT   CROSSLNK    560    560       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT   CROSSLNK    701    701       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:25218447,
FT                                ECO:0000244|PubMed:25755297,
FT                                ECO:0000244|PubMed:25772364}.
FT   VAR_SEQ       1     65       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:11278651}.
FT                                /FTId=VSP_017916.
FT   VAR_SEQ      66     66       E -> M (in isoform 2).
FT                                {ECO:0000303|PubMed:11278651}.
FT                                /FTId=VSP_017917.
FT   VARIANT     154    154       A -> T (in dbSNP:rs17855104).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_037629.
FT   VARIANT     517    517       E -> K (in dbSNP:rs17855103).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_037630.
FT   VARIANT     749    749       N -> D (in dbSNP:rs17857515).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_037631.
FT   VARIANT     812    812       P -> R (in dbSNP:rs36034138).
FT                                /FTId=VAR_037632.
FT   MUTAGEN      76     76       K->R: No effect on sumoylation.
FT                                {ECO:0000269|PubMed:14516784}.
FT   MUTAGEN      98     98       S->A: Loss of phosphorylation but no
FT                                effect on E3 ubiquitin-protein ligase
FT                                activity. {ECO:0000269|PubMed:19053840}.
FT   MUTAGEN      98     98       S->D: Increase in E3 ubiquitin-protein
FT                                ligase activity and increased binding to
FT                                UBE2D1. No effect on SUMO1-protein ligase
FT                                activity. {ECO:0000269|PubMed:19053840}.
FT   MUTAGEN     131    131       W->A: Abrogates E3 ubiquitin-protein
FT                                ligase activity.
FT                                {ECO:0000269|PubMed:15247280}.
FT   MUTAGEN     301    301       K->R: No effect on sumoylation.
FT                                {ECO:0000269|PubMed:14516784}.
FT   MUTAGEN     485    485       K->R: No effect on sumoylation.
FT                                {ECO:0000269|PubMed:14516784}.
FT   MUTAGEN     560    560       K->R: Strongly reduces sumoylation.
FT                                {ECO:0000269|PubMed:14516784}.
FT   MUTAGEN     718    718       S->A: Loss of phosphorylation by PLK1 and
FT                                increases in p53/TP53 stability.
FT                                {ECO:0000269|PubMed:19473992}.
FT   MUTAGEN     921    921       K->R: No effect on sumoylation.
FT                                {ECO:0000269|PubMed:14516784}.
FT   CONFLICT    124    125       CF -> K (in Ref. 5; AAC98530).
FT                                {ECO:0000305}.
FT   CONFLICT    257    257       N -> S (in Ref. 1; AAD23379).
FT                                {ECO:0000305}.
FT   CONFLICT    308    308       F -> S (in Ref. 1; AAD23379).
FT                                {ECO:0000305}.
FT   CONFLICT    922    922       E -> G (in Ref. 1; AAD23379).
FT                                {ECO:0000305}.
FT   CONFLICT   1040   1040       R -> K (in Ref. 1; AAD23379).
FT                                {ECO:0000305}.
SQ   SEQUENCE   1045 AA;  119198 MW;  3DA635FDB5C83B77 CRC64;
     MGSQPPLGSP LSREEGEAPP PAPASEGRRR SRRVRLRGSC RHRPSFLGCR ELAASAPARP
     APASSEIMAS AAKEFKMDNF SPKAGTSKLQ QTVPADASPD SKCPICLDRF DNVSYLDRCL
     HKFCFRCVQE WSKNKAECPL CKQPFDSIFH SVRAEDDFKE YVLRPSYNGS FVTPDRRFRY
     RTTLTRERNA SVYSPSGPVN RRTTTPPDSG VLFEGLGIST RPRDVEIPQF MRQIAVRRPT
     TADERSLRKI QEQDIINFRR TLYRAGARVR NIEDGGRYRD ISAEFFRRNP ACLHRLVPWL
     KRELTVLFGA HGSLVNIVQH IIMSNVTRYD LESQAFVSDL RPFLLNRTEH FIHEFISFAR
     SPFNMAAFDQ HANYDCPAPS YEEGSHSDSS VITISPDEAE TQELDINVAT VSQAPWDDET
     PGPSYSSSEQ VHVTMSSLLN TSDSSDEELV TGGATSQIQG VQTNDDLNND SDDSSDNCVI
     VGFVKPLAER TPELVELSSD SEDLGSYEKM ETVKTQEQEQ SYSSGDSDVS RCSSPHSVLG
     KDEQINKGHC DSSTRIKSKK EEKRSTSLSS PRNLNSSVRG DRVYSPYNHR HRKRGRSRSS
     DSRSQSRSGH DQKNHRKHHG KKRMKSKRSR SRESSRPRGR RDKKRSRTRD SSWSRRSQTL
     SLSSESTSRS RSRSSDHGKR RSRSRNRDRY YLRNNYGSRY KWEYTYYSRN KDRDGYESSY
     RRRTLSRAHY SRQSSSPEFR VQSFSERTNA RKKNNHSERK YYYYERHRSR SLSSNRSRTA
     STGTDRVRNE KPGGKRKYKT RHLEGTNEVA QPSREFASKA KDSHYQKSSS KLDGNYKNES
     DTFSDSRSSD RETKHKRRKR KTRSLSVEIV YEGKATDTTK HHKKKKKKHK KKHKKHHGDN
     ASRSPVVITI DSDSDKDSEV KEDTECDNSG PQDPLQNEFL APSLEPFETK DVVTIEAEFG
     VLDKECDIAT LSNNLNNANK TVDNIPPLAA SVEQTLDVRE ESTFVSDLEN QPSNIVSLQT
     EPSRQLPSPR TSLMSVCLGR DCDMS
//
